This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (353) Malaria Surveillance and Prevention (26)

Published on in Vol 5, No 2 (2016): Apr-Jun

Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial

Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial

Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial

Authors of this article:

Juliana N. Anyanwu1 Author Orcid Image ;   Olatundun Williams2 Author Orcid Image ;   Casey L. Sautter1 Author Orcid Image ;   Phillip Kasirye3 Author Orcid Image ;   Heather Hume3, 4 Author Orcid Image ;   Robert O. Opoka3 Author Orcid Image ;   Teresa Latham5 Author Orcid Image ;   Christopher Ndugwa3 Author Orcid Image ;   Russell E. Ware5 Author Orcid Image ;   Chandy C. John6 Author Orcid Image
Article Authors Cited by (19) Tweetations (1) Metrics

Journals

  1. Carman A, Sautter C, Anyanwu J, Ssemata A, Opoka R, Ware R, Rujumba J, John C. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood & Cancer 2020;67(2) View
  2. Power-Hays A, Ware R. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology 2020;27(3):172 View
  3. Green N, Munube D, Bangirana P, Buluma L, Kebirungi B, Opoka R, Mupere E, Kasirye P, Kiguli S, Birabwa A, Kawooya M, Lubowa S, Sekibira R, Kayongo E, Hume H, Elkind M, Peng W, Li G, Rosano C, LaRussa P, Minja F, Boehme A, Idro R. Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study. BMC Pediatrics 2019;19(1) View
  4. Smart L, Hernandez A, Ware R. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology 2018;55(2):102 View
  5. Ware R, de Montalembert M, Tshilolo L, Abboud M. Sickle cell disease. The Lancet 2017;390(10091):311 View
  6. Epting C, Emmer B, Du N, Taylor J, Makanji M, Olson C, Engman D, Weiss L, Docampo R, Tanowitz H. Cell Cycle Inhibition To Treat Sleeping Sickness. mBio 2017;8(5) View
  7. McGann P, Hernandez A, Ware R. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood 2017;129(2):155 View
  8. Opoka R, Ndugwa C, Latham T, Lane A, Hume H, Kasirye P, Hodges J, Ware R, John C. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood 2017;130(24):2585 View
  9. Nevitt S, Jones A, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2017;2017(4) View
  10. John C, Opoka R, Latham T, Hume H, Nabaggala C, Kasirye P, Ndugwa C, Lane A, Ware R. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine 2020;382(26):2524 View
  11. Nartey E, Spector J, Adu-Afarwuah S, Jones C, Jackson A, Ohemeng A, Shah R, Koryo-Dabrah A, Kuma A, Hyacinth H, Steiner-Asiedu M. Nutritional perspectives on sickle cell disease in Africa: a systematic review. BMC Nutrition 2021;7(1) View
  12. Rankine-Mullings A, Nevitt S. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2022;2022(10) View
  13. Esoh K, Wonkam-Tingang E, Wonkam A. Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care. The Lancet Haematology 2021;8(10):e744 View
  14. Dexter D, McGann P. Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2023;43(5):430 View
  15. Awor S, Bongomin F, Kaggwa M, Pebalo F, Musoke D. Prevalence of Use of Herbal Medicines for the Treatment of Sickle Cell Disease in Africa: a Systematic Review and Meta-analysis. Journal of Herbal Medicine 2023;42:100735 View
  16. Santos B, Ginete C, Gonçalves E, Delgadinho M, Miranda A, Faustino P, Arez A, Brito M. Characterization of a cohort of Angolan children with sickle cell anemia treated with hydroxyurea. Blood Cells, Molecules, and Diseases 2024;105:102822 View
  17. Drown L, Osei M, Thapa A, Boudreaux C, Archer N, Bukhman G, Adler A. Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review. The Lancet Haematology 2024;11(4):e299 View
  18. Siegert T, Opoka R, Nakafeero M, Carman A, Mellencamp K, Latham T, Hume H, Lane A, Ware R, Ssenkusu J, John C, Conroy A. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy. Blood Vessels, Thrombosis & Hemostasis 2024;1(1):100001 View

Books/Policy Documents

  1. Anderson C, Darbari D. Sickle Cell Disease and Hematopoietic Stem Cell Transplantation. View